Joseph F. McGuire is recorded as CFO at Nexgel, Inc. (NXGL) since January 1, 2025. Earlier roles on record: CFO at MAIA Biotechnology, Inc. (MAIA) until November 10, 2023. Nexgel, Inc. reported in an 8-K filed January 7, 2026 that Joseph F. McGuire was terminated as Chief Financial Officer, effective December 31, 2025. Nexgel, Inc. reported in an 8-K filed January 6, 2025 that Joseph F. McGuire was appointed Chief Financial Officer, effective January 1, 2025. The proxy statement of Nexgel, Inc. reports total compensation of $446,169 for Joseph F. McGuire in fiscal 2025, including a base salary of $190,769. Disclosed compensation is on record for 3 fiscal years. Joseph F. McGuire has spoken on 2 earnings calls across 1 company, most recently for Nexgel, Inc. on November 12, 2025. Nexgel, Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Nexgel, Inc. includes Brian Kieser (CEO), Adam E. Drapczuk III (CFO), Ian Blackman (CFO) and 7 others.
“Mr. Drapczuk replaced Joseph F. McGuire, whose employment with the Company terminated effective as of December 31, 2025.”
Nexgel, Inc. Form 8-K, filed January 7, 2026
· Read the filing
“Effective January 1, 2025, the Company appointed Joseph F. McGuire as the Company’s Chief Financial Officer and designated him as principal financial officer and principal accounting officer.”
Nexgel, Inc. Form 8-K, filed January 6, 2025
· Read the filing
Joseph F. McGuire on recent calls
“Today, I'll review our key financial results for 2025. For 2025, revenue totaled $2.9 million, flat as compared to $2.9 million for 2024. Contract manufacturing and branded product revenue remained stable year over year.”
“Today, I'll review our key financial results for Q2 2025. For the second quarter of 2025, revenue totaled $2.88 million, an increase of 100.3% compared to $1.44 million for the second quarter of 2024.”
